Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

AXGT

Axovant Gene Therapies (AXGT)

Axovant Gene Therapies Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AXGT
FechaHoraFuenteTítuloSímboloCompañía
25/04/202315:05Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202315:17Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202315:14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AXGTAxovant Gene Therapies Ltd
12/04/202307:52Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202315:08Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202315:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/03/202305:03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
21/02/202315:06Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/02/202305:47Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/02/202307:53Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202315:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:AXGTAxovant Gene Therapies Ltd
09/02/202305:01Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/06/202206:02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202216:08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/10/202116:19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/08/202115:15Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
16/12/202006:00Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AXGTAxovant Gene Therapies Ltd
02/12/202006:00GlobeNewswire Inc.Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangl...NASDAQ:AXGTAxovant Gene Therapies Ltd
20/11/202005:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AXGTAxovant Gene Therapies Ltd
19/11/202007:00GlobeNewswire Inc.Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific AdvisorNASDAQ:AXGTAxovant Gene Therapies Ltd
13/11/202006:06Edgar (US Regulatory)Registration of Securities of Successor Issuers (8-k12g3)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/11/202006:00GlobeNewswire Inc.Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202016:11Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202006:00GlobeNewswire Inc.Axovant Gene Therapies Announces Name Change to Sio Gene TherapiesNASDAQ:AXGTAxovant Gene Therapies Ltd
09/11/202006:00GlobeNewswire Inc.Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff DiseasesNASDAQ:AXGTAxovant Gene Therapies Ltd
29/10/202015:01GlobeNewswire Inc.Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 202...NASDAQ:AXGTAxovant Gene Therapies Ltd
22/10/202006:00GlobeNewswire Inc.Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020NASDAQ:AXGTAxovant Gene Therapies Ltd
13/10/202006:00GlobeNewswire Inc.Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff DiseaseNASDAQ:AXGTAxovant Gene Therapies Ltd
09/10/202006:00GlobeNewswire Inc.Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 GangliosidosisNASDAQ:AXGTAxovant Gene Therapies Ltd
08/10/202006:00GlobeNewswire Inc.Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial OfficerNASDAQ:AXGTAxovant Gene Therapies Ltd
 Showing the most relevant articles for your search:NASDAQ:AXGT

Su Consulta Reciente

Delayed Upgrade Clock